Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 3/20 | 0.38 |
| ▸ | PLK1 | P53350 | 3/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.35 |
| ▸ | RARB | P10826 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553925 | 0.94 | SLC16A3 (0.40) | SLC16A3SCDGRM4BCL2BCL2L1 | |
| SCHEMBL3555276 | 0.81 | SLC16A3 (0.47) | SLC16A3PLK1PLK3RARBMEN1 | |
| SCHEMBL3561014 | 0.81 | SLC16A3 (0.54) | SLC16A3GRM4BCL2BCL2L1 | |
| SCHEMBL3553932 | 0.80 | SLC16A3 (0.46) | SLC16A3PLK1PLK3RARBMEN1 | |
| SCHEMBL3557951 | 0.80 | SLC16A3 (0.48) | SLC16A3PLK1PLK3RARBMEN1 | |
| SCHEMBL3558694 | 0.79 | ALOX5 (0.40) | PLK1PLK3GRM4RARBMEN1 | |
| SCHEMBL3558700 | 0.78 | GRM4 (0.40) | SLC16A3SCDGRM4KMT2ABCL2 | |
| SCHEMBL3553579 | 0.78 | SLC16A3 (0.46) | SLC16A3PLK1PLK3RARBMEN1 | |
| SCHEMBL3561330 | 0.78 | SLC16A3 (0.42) | SLC16A3PLK1PLK3RARBALDH1A1 | |
| SCHEMBL3555111 | 0.78 | PLK1 (0.46) | SLC16A3PLK1PLK3RARBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885SCD 365/4885PLK1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.